

<http://www.sartorius-stedim.com/>

Sartorius Stedim Biotech: Document availability communications

AUBAGNE, France & GOETTINGEN, Germany--([BUSINESS WIRE](#))-- Regulatory News:
Sartorius Stedim Biotech (Paris:DIM):

The Sartorius Stedim Biotech Group First-Half Financial Report January to June 2009 is now available at www.sartorius-stedim.com.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions” on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.

Contacts

Sartorius Stedim Biotech
Dominic Grone ; Group Communications
Tel. : +49 (0)551/ 308-3324; Fax : +49 (0)551/ 308-3572 ;
Email : dominic.grone@sartorius.com
www.sartorius-stedim.com

Source: Sartorius Stedim Biotech

<http://www.businesswire.com/http://www.businesswire.com/>

View this news release online at:

<http://www.businesswire.com/news/home/20090803000000/en>